

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
H. Arima, et al.

Serial No.: 09/720,363 ✓

Filed: December 22, 2000

For: Antisense Oligonucleotide Inhibiting IL-10 Protein Expression

Art Unit: To Be Assigned

Examiner: To Be Assigned

SUBMISSION OF SEQUENCE LISTING PURSUANT TO
UNDER 37 C.F.R. 1.821, 1.822, 1.825 and 1.832

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

ATTENTION: BOX SEQUENCE LISTING

Sir:

Responsive to the Notification To Comply With Requirements For Patent Applications
Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures mailed on
September 20, 2001 in the above identified application, submitted herewith in the above
identified pending U.S. Patent Application is a substitute computer readable form (CRF) of the
"Sequence Listing".

The undersigned hereby states that the content of the computer readable form (CRF)
attached hereto of the Sequence Listing, submitted in accordance with 37 CFR 1.821(e), 1.821(f),
1.821(g), 1.825(b) and 1.825(d), respectively, contains no new matter, and contains the same
Sequence Listings as originally filed in the case. The attached substitute CRF is filed merely to
place the Sequence Listings in CRF in a form complying with the requirements listed above.

I hereby declare that all statements made herein of my own knowledge are true and that
all statements made on information and belief are believed to be true; and further that these
statements were made with the knowledge that willful false statements and the like so made are

punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

Donald E. Townsend, Jr.

Donald E. Townsend, Jr.
Reg. No. 43,198

Date: October 17, 2001

TOWNSEND & BANTA
1225 Eye St., N.W.
Suite 500, #50028
Washington, D.C. 20009
(202) 682-4727